From biologics to treatments for rare diseases, these drugs bring unique production challenges that require advanced technologies and precise processes.
The San Diego-based CDMO said it made the decision to “right size” its Durham, N.C. facility “based on demand in the gene therapy sector, which requires reducing headcount.”
Boehringer Ingelheim has licensed Lonza-owned Synaffix’s antibody-drug conjugate technology, while Samsung Biologics is expanding ADC services through a new partnership with LigaChem Biosciences.
